ABOS

Acumen Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.530

+0.17(12.500%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.600

Open

1.360

VWAP

1.51

Vol

922.30K

Mkt Cap

92.68M

Low

1.360

Amount

1.39M

EV/EBITDA(TTM)

Total Shares

60.08M

-31.11M

EV/OCF(TTM)

P/S(TTM)

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

2 Analyst Rating

Wall Street analysts forecast ABOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABOS is 7.00 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.530

Low

4.00

Averages

7.00

High

10.00

Current: 1.530

Low

4.00

Averages

7.00

High

10.00

Citi

Buy

initiated

2025-06-18

Reason

Citi

Price Target

2025-06-18

initiated

Buy

Reason

Citi initiated coverage of Acumen (ACUM) with a Buy rating and $4 price target. Acumen is a clinical stage biotech company currently developing sabirnetug for the treatment of Alzheimer's disease by selectively targeting toxic AN2 oligomers, the analyst tells investors in a research note. The firm says Acumen is utilizing a novel approach by only attacking toxic AN2 oligomers with IV sabirnetug, whereas other companies' monoclonal antibodies target other less-toxic AN2O species such as monomers, protofibrils or mature plaques. It believes the company has generated "early yet promising" Phase 1 data, which suggests sabirnetug reduces amyloid plaques at a similar rate and magnitude to Biogen's (BIIB) Leqembi at comparable time points, alongside a safety profile that betters current on-the-market therapies. Citi views the large unmet need in Alzheimer's as a space that can hold multiple players including sabirnetug.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$15 → $11

2025-03-28

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$15 → $11

2025-03-28

Maintains

Strong Buy

Reason

UBS

Colin Bristow

Strong Buy

Maintains

$6 → $4

2025-03-28

Reason

UBS

Colin Bristow

Price Target

$6 → $4

2025-03-28

Maintains

Strong Buy

Reason

UBS lowered the firm's price target on Acumen to $4 from $6 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company's cash position and the market volatility for the target cut.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$15

2024-11-13

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$15

2024-11-13

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$15

2024-10-03

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$15

2024-10-03

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Acumen Pharmaceuticals Inc (ABOS.O) is -0.71, compared to its 5-year average forward P/E of -7.66. For a more detailed relative valuation and DCF analysis to assess Acumen Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.66

Current PE

-0.71

Overvalued PE

6.58

Undervalued PE

-21.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.26

Current EV/EBITDA

0.38

Overvalued EV/EBITDA

5.36

Undervalued EV/EBITDA

-9.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

122.46

Current PS

0.00

Overvalued PS

604.41

Undervalued PS

-359.50

Financials

Annual

Quarterly

FY2025Q2

N/A

Total Revenue

FY2025Q2

YoY :

+71.24%

-41.75M

Operating Profit

FY2025Q2

YoY :

+99.40%

-40.95M

Net Income after Tax

FY2025Q2

YoY :

+100.00%

-0.68

EPS - Diluted

FY2025Q2

YoY :

+92.39%

-31.84M

Free Cash Flow

FY2025Q2

N/A

Gross Profit Margin - %

FY2025Q2

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

259.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

259.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABOS News & Events

Events Timeline

2025-08-12 (ET)

2025-08-12

07:06:44

Acumen sees cash runway into early 2027

2025-08-12

07:06:22

Acumen reports Q2 EPS (68c), consensus (52c)

2025-07-28 (ET)

2025-07-28

08:07:57

Acumen presents results from its Phase 2 ALTITUDE-AD study of sabirnetug

News

9.0

07-28NASDAQ.COM

Acumen Pharma Cuts Alzheimer's Trial Costs 40% With Blood Test

7.5

07-15NASDAQ.COM

Acumen, JCR Pharma Join To Develop Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimers

7.5

07-15Newsfilter

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer's Disease